I det kliniske program forekom der generelt leverenzymændringer inden for de første 26 uger af behandlingen, i reglen udviklet gradvist og hovedsageligt asymptomatisk.
In the clinical programme, liver enzyme changes generally occurred within the first 26 weeks of treatment, usually developed gradually, and were mainly asymptomatic.